{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:47:31Z","timestamp":1791247651466,"version":"4.1.0"},"reference-count":16,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2005,3,8]],"date-time":"2005-03-08T00:00:00Z","timestamp":1110240000000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2005,3]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>It is becoming increasingly clear that, during successful highly active antiretroviral therapy (HAART), a proportion of treated patients develop opportunistic infections (OIs), referred to in this setting as immune restoration disease (IRD). We examined the risk of developing IRD in HAART\u2010treated HIV\u2010infected patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective study of a cohort including all 389 patients treated with HAART between 1 January 1998 and 31 May 2004 in our HIV unit was performed to evaluate the occurrence of and risk factors for IRD during HAART. Baseline and follow\u2010up values of CD4 T\u2010cell counts and plasma viral loads (pVLs) were compared to assess the success of HAART.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>During successful HAART (significant increase in CD4 T\u2010cell counts and decrease in pVL), at least one IRD episode occurred in 65 patients (16.7%). The median time to IRD was 4.6 months (range 2\u201312 months). IRDs included dermatomal herpes zoster (26 patients), pulmonary tuberculosis (four patients), tuberculous exudative pericarditis (two patients), tuberculous lymphadenitis (two patients), cerebral toxoplasmosis (one patient), progressive multifocal leucoencephalopathy (PML) (one patient), inflamed molluscum (one patient), inflamed <jats:italic>Candida<\/jats:italic><jats:italic>albicans<\/jats:italic> angular cheilitis (three patients), genital herpes simplex (two patients), tinea corporis (two patients), cytomegalovirus (CMV) retinitis (two patients), CMV vitritis (one patient) and hepatitis B (three patients) or C (fifteen patients). A baseline CD4 T\u2010cell count below 100 cells\/\u03bcL was shown to be the single predictor [odds ratio (OR) 2.5, 95% confidence interval (CI) 0.9\u20136.4] of IRD, while a CD4 T\u2010cell count increase to &gt;400 cells\/\u03bcL, but not undetectable pVL, was a negative predictor of IRD (OR 0.3, 95% CI 0.1\u20130.8).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>To avoid IRD in advanced patients, HAART should be initiated before the CD4 T\u2010cell count falls below 100 cells\/\u03bcL.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2005.00277.x","type":"journal-article","created":{"date-parts":[[2005,3,8]],"date-time":"2005-03-08T22:28:13Z","timestamp":1110320893000},"page":"140-143","source":"Crossref","is-referenced-by-count":109,"title":["The prevalence and risk of immune restoration disease in HIV\u2010infected patients treated with highly active antiretroviral therapy"],"prefix":"10.1111","volume":"6","author":[{"given":"DJ","family":"Jevtovi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Salemovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Ranin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Pe\u0161i\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"\u017derjav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Djurkovi\u0107\u2010Djakovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,3,8]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"S157","article-title":"Altered natural history of AIDS\u2010related opportunistic infections in the era of potent combination anti\u2010retroviral therapy","volume":"12","author":"Jacobson MA","year":"1998","journal-title":"AIDS"},{"key":"e_1_2_6_3_2","first-page":"46","article-title":"Immune restoration disease in HIV patients","volume":"7","author":"French MA","year":"2002","journal-title":"aberrant immune responses after antiretroviral therapy"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1293.2000.00012.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1998.tb123372.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.158.1.9712001"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199814000-00013"},{"key":"e_1_2_6_8_2","first-page":"1719","article-title":"Herpes zoster infection in HIV\u2010seropositive patients associated with highly active anti\u2010retroviral therapy","volume":"12","author":"Aldeen T","year":"1998","journal-title":"AIDS"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/515019"},{"key":"e_1_2_6_10_2","unstructured":"Duni\u0107I Djurkovi\u0107\u2010Djakovi\u0107O Vesi\u0107Set al. Herpes zoster as an immune restoration disease in AIDS patients during therapy incuding protease inhibitors.Int J STD AIDSin press."},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.114.3.933"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/13550280152537247"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000131375.21070.06"},{"key":"e_1_2_6_14_2","first-page":"51","article-title":"Immune reconstitution under highly active antiretroviral therapy (HAART)","volume":"1","author":"Carcelain G","year":"1999","journal-title":"AIDS Rev"},{"key":"e_1_2_6_15_2","first-page":"S25","article-title":"Immune reconstitution in HIV infection","volume":"13","author":"Gea\u2010Banacloche JC","year":"1999","journal-title":"AIDS"},{"key":"e_1_2_6_16_2","first-page":"67","article-title":"The immune reconstitution inflammatory syndrome","volume":"5","author":"Shelburne SA III","year":"2003","journal-title":"AIDS Rev"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2004.00185.x"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2005.00277.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2005.00277.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T15:03:38Z","timestamp":1696950218000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2005.00277.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["10.1111\/j.1468-1293.2005.00277.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2005.00277.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}